Moderna's mRNA flu vaccine receives FDA approval

The FDA has approved Moderna’s mFLUSIVA, the first mRNA-powered influenza vaccine. This approval marks a transition from traditional egg-based manufacturing to a genetic blueprint method that allows for faster production and better alignment with circulating virus strains.

Traditional flu vaccines rely on slow processes that can lead to virus mutations during production, potentially reducing effectiveness. In contrast, mRNA technology provides cells with instructions to produce specific viral proteins, such as hemagglutinin, enabling rapid redesigns to meet seasonal antigenic drift. The platform is also modular, allowing for the potential combination of multiple respiratory virus strains in a single injection.

The approval comes amid political shifts in research funding, as Health Secretary Robert F. Kennedy Jr. has cancelled 22 government-backed projects intended to advance mRNA technology through the Biomedical Advanced Research and Development Authority (BARDA). The FDA has approved the vaccine for individuals aged 50 to 64 and is fast-tracking approval for adults aged 65 and older.